Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects

Soja Shamizadeh, Knut Brockow, Johannes Ring

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations

Abstract

Rupatadine is a modern non-sedating H1-antihistamine that also haswith additional antagonist effects on platelet-activating factor (PAF). Under the tradenames Rupafin® and Urtimed®, Rrupatadine is approvedregistered in Germany for the treatment of allergic rhinitis and urticaria infor adults and children aged over 12 years. In this review, the available literature available to date onregarding the pharmacological profile and clinical application of Rrupatadine is reviewed and compared to other conventional histamines. In conclusionFinally, the side effects, safety and interaction profileincompatibility of Rrupatadine are discussed. Due to CYP p450 metabolism, Rrupatadine should not be given together with Eerythromycin, Kketoconazole or grapefruit juice. Rupatadine has been found to be effective and safe Iin a variety of randomized clinical trials both in both seasonal and perennial allergic rhinitis, as well as inbut also chronic urticaria Rupatadine has been found as effective and safe.

Original languageEnglish
Pages (from-to)87-95
Number of pages9
JournalAllergo Journal International
Volume23
Issue number3
DOIs
StatePublished - May 2014

Keywords

  • Antihistamines
  • Rupatadine
  • allergic rhinitis
  • chronic urticaria
  • platelet-activating factor

Fingerprint

Dive into the research topics of 'Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects'. Together they form a unique fingerprint.

Cite this